Commercial Bribery Will Be Transferred To Pharmaceutical Enterprises.

Recently, the letter of the National Health Insurance Bureau on Soliciting Opinions on the establishment of drug price and recruitment credit evaluation system (Draft) has been circulated in the industry. This letter shows that the National Health Insurance Bureau will make rational use of relevant departments to crack down on and deal with commercial bribery in the medical field, manipulate market law enforcement results, and adopt appropriate disciplinary measures for breach of faith through corporate commitment and contract management.

In April 29th, Wang Ying, CEO, told reporters in an interview with twenty-first Century economic report that the newly revised "Drug Administration Law" also increased the prohibition of commercial bribery. In the list of administrative enforcement of the National Health Insurance Bureau in 2020, there were also related matters related to the commercial bribery inspection.

Wang Hongzhi, partner of Peking University Management Consulting Group, told reporters in twenty-first Century that the disciplinary measures were mainly bribe taking and bribe taking. In addition to GSK, no production enterprise was retrieved because the bribe was prosecuted by the judiciary. Therefore, it is hoped that the establishment of evaluation and disciplinary system can also trace the source of corporate behavior.

"This is not the new initiative of the health insurance bureau, but the continuation and improvement of the policy. It is more clear about bribery and punishment, and it is clear that commercial bribery will be accountable to pharmaceutical companies. This also means that the past dealer mode will also change, and we need to do well in compliance and services. According to our previous research on the two vote system, pharmaceutical companies will also move towards semi self operation under the guidance of policies, and ultimately to self run. Wang Ying said.

This means that pharmaceutical enterprises, while enjoying full autonomy in pricing and self managing legitimate rights, are also faced with the norms of trustworthiness encouragement and dishonesty. -IC photo

Accountable to pharmaceutical companies

According to the above draft, the establishment of the drug price and recruitment credit evaluation system follows five basic principles, including social co governance, power and responsibility equivalence, hierarchical response, dynamic management and collaborative linkage.

This means that relying on the national unified drug procurement market, pharmaceutical enterprises are fully regulated and have the right to operate independently, while they are also faced with the norms of trustworthiness incentives and dishonesty.

Specifically, it includes six contents: establishing a pharmaceutical company's price and marketing behavior, keeping promise, reporting voluntarily, investigating information, evaluating credit, grading rewards and punishments, and credit repair.

Enterprises must commit themselves to putting an end to commercial bribery and do not give financial or other illegitimate interests to persons in charge of public hospitals, drug purchasers, doctors, pharmacists, and other relevant personnel who purchase and use drugs. Commitment to eliminate manipulation of market behavior, do not take advantage of monopoly or market dominance to manipulate prices to obtain illegitimate interests.

As well as commitments committed to entrusting service enterprises and agencies to conduct commercial bribery and manipulation of the market for their own drugs, and jointly bear the disciplinary responsibility of price and recruit credit. When undertaking promises of dishonesty, the medical insurance department accepts price and recruit credit punishment measures.

Wang Ying told reporters on twenty-first Century economic report that in the past, enterprises would also write commitments in bidding, but in the purchase and sale of links, bribery and other problems occurred in the past, penal representatives and distributors were punished, and few enterprises were punished.

Wang Hongzhi said that in the past, the punishment measures mainly focused on bribes and bribe taking. In addition to GSK, no production enterprise was retrieved because the bribe was prosecuted by the judiciary.

However, after the implementation of the above six drug prices and recruitment credit evaluation system, it is difficult for enterprises to remain aloof.

"Later, boards will fight in enterprises, dealers may run, but ultimately pharmaceutical companies can be traced back as the main body of responsibility to assume responsibility. And after the institutional reform, the national health insurance agency can better manage the whole country. Wang Ying said.

2019 throughout the year, the National Health Insurance Agency organized 69 inspection teams as a law enforcement body to conduct a nationwide flight inspection, covering 30 provinces and 149 medical institutions. The total amount of suspected illegal offense was 2 billion 226 million yuan. In June of that year, the Ministry of finance supervision and Evaluation Bureau, together with the fund supervision department of the National Health Insurance Bureau, randomly selected 77 medical enterprise inspection lists and carried out accounting information in the pharmaceutical industry. Quality testing.

Just a few days ago, the state medical bureau also issued the list of administrative law enforcement matters of the National Health Protection Bureau (2020 Edition), covering 16 projects, involving medical institutions, enterprises and natural persons. In the 16 administrative enforcement matters, the fund supervision department has undertaken 11 items, and the medical price and tendering procurement department has handled 4 items, and the medical insurance undertakings Management Center has undertaken 1 items. Including administrative compulsory (1), administrative penalties (7 items), administrative examination (9 items) three categories of administrative categories, the implementation of objects covered by medical insurance agencies, medical institutions, drug management units and other medical insurance service institutions, employers, pharmaceutical enterprises and natural persons.

Business mode change

From the big reduction of procurement links, the key monitoring of the use links, and the construction of medical and health departments, all of them point to the grey areas in the field of medicine purchase and sale. In the newly revised "Drug Administration Law", the regulations on the prohibition of business bribery have also been increased. In the list of administrative enforcement of the National Health Insurance Bureau in 2020, there were also related matters related to the commercial bribery inspection.

Wang Ying pointed out to the twenty-first Century economic report reporter that the punishment measures and discredit system for enterprises are actually a commonplace problem. But the difference is that it is clear that pharmaceutical companies should be the main body of responsibility, and agents bribes need to be "connected".

"The entrusted dealers are irregularities, and the production enterprises need to be jointly and severally liable. This means that pharmaceutical companies and distributors need to make changes. In the future, the production enterprises will go to semi self operation, and finally go to self operation. Wang Ying said, after the channel can not self control enterprises, the cost can not meet the national bidding price requirements of enterprises, destined to be eliminated.

Shi Lichen, head of Beijing Ding Chen medical management center, pointed out to the twenty-first Century economic report reporter that only a small number of pharmaceutical enterprises in China have their own control sales teams, and most of them take agency mode. The transformation of pharmaceutical enterprises based on agent mode should transform the marketing system to cope with the great changes in the industry in the future.

Shi Lichen pointed out that the pharmaceutical marketing enterprises based on agency mode are simple: the investment system is the main business, and the market, logistics or sales management are subsidiary. Under the new situation, this simple marketing system is no longer applicable, which needs to be adjusted according to the market and policy situation.

"Previous irregularities, commercial bribery is mostly the dealer is engaged in, the enterprise can also have a firewall, now this policy, dealer irregularities also calculate the joint liability of enterprises, dealer system completely needs to be changed." Wang Ying said.

In fact, in the past two years, the price of 4+7 countries has been squeezed to the limit, and the channels and quantities have been promised by the state. The dealer system must also be transformed into a distribution provider, an academic service provider, a government service provider or an after sales service provider, otherwise it will be eliminated.